ストックスクリーナーアプリを入手
0.56
6.79%
-0.0408
アフターアワーズ：
.56
Evogene Ltd (EVGN) 最新ニュース
Earnings To Watch: Evogene Ltd (EVGN) Q2 2026 -- GF Value Sees 15% Downside - Yahoo Finance
Freightos Names Yaron Eldad as Chief Financial Officer - marketscreener.com
EVGN Q2'26 Earnings: EPS estimate is (0.27) USD - TradingView
Armistice Capital (EVGN) discloses 4.99% beneficial stake in Evogene shares - Stock Titan
Evogene chairman to address dissident shareholder issues in Aug 18 earnings call - Pluang
Evogene Chairman Joins Company Results Call on August 18 - Stock Titan
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene Ltd. (EVGN) investors lift beneficial stake to 19.35% of shares - Stock Titan
Evogene (EVGN): Director Leon Recanati buys 460,000 shares, now holds 8.6% - Stock Titan
Evogene (EVGN) director Leon Recanati buys 460,000 shares and reports option holdings - Stock Titan
Earnings Preview: Evogene to Report Financial Results Pre-market on August 18 - Moomoo
Leon Recanati Discloses Investment at Evogene Ltd. with 5.7% Stake - TradingView
Evogene (EVGN) director Leon Recanati buys 800,000 shares, lifts stake to 5.7% - Stock Titan
Evogene (EVGN) Insider Trading Activity 2026 - MarketBeat
Evogene Ltd. (EVGN) investor group boosts ownership to 15.98% - Stock Titan
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene (NASDAQ: EVGN) Share Price, EVGN Stock News, EVGN Share Price & Updates - Kalkine
Evogene Ltd. (EVGN) director boosts stake with 800,000-share buy - Stock Titan
ICL and Lavie Bio leverage AI for the development of yield increasing Bio-Stimulants - AgroSpectrum India
Evogene Sets Sept. 4 AGM Amid Board Contest and VP Departure - The Globe and Mail
Evogene Ltd. Revenue Breakdown – NASDAQ:EVGN - TradingView
Evogene (Nasdaq: EVGN) faces proxy slate battle and reverse split decision - Stock Titan
Evogene Ltd (EVGN) Struggles Near Support as Selling Pressure PersistsNarrow Range Breakout - dars.gov.et
Evogene to release Q2 2026 financial results an... - Pluang
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 13D/A Evogene Ltd. For: 27 July By Investing.com - Investing.com South Africa
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd. (EVGN) holders report 17.41% stake and new ADS buys - Stock Titan
Evogene Ltd (EVGN) Balance Sheet - TradingKey
EVGN|Evogene Ltd|Price:0.542|Chg%:-0.006 - TradingKey
Evogene Ltd (EVGN) Cash Flow - TradingKey
AI is rewiring future of energy cropsOfer Haviv, CEO, Evogene (EVGN) - AgroSpectrum India
Evogene and ELEO join forces to develop next-gen oral PCSK9 drugs targeting billion-dollar cardio market - Indian Pharma Post
EVGN|Evogene Ltd|Price:0.655|Chg%:+0.119 - TradingKey
Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evogene Ltd (EVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evogene Ltd (EVGN) Income Statement - TradingKey
Evogene Ltd. (EVGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Evogene Ltd (EVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evogene and ELEO to develop new oral PCSK9 inhibitors - Pharmaceutical Business review -
Evogene Ltd. (EVGN) stock price, news, quote and history - Yahoo Finance UK
Evogene and Eleo collaborate to discover PCSK9 pathway inhibitors - BioWorld News
Evogene (EVGN) Q1 2026 Earnings: Wider-than-Expected Loss Amid Ongoing R&D InvestmentsEarnings Analysis - dars.gov.et
Evogene and ELEO partner on oral PCSK9 inhibitor development By Investing.com - Investing.com South Africa
Evogene & ELEO Partner on Oral PCSK9 Inhibitors - AllSci
Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors - Moomoo
Evogene and ELEO partner on oral PCSK9 inhibitor development - Investing.com
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases – Company Announcement - Financial Times
Evogene stock trades quietly as genomics group leans on cash and recent revenue growth - Ad-hoc-news.de
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases - PR Newswire
Evogene (EVGN) investors add 202K ADSs, now hold 16.81% stake - Stock Titan
Evogene Expands ATM Offering as Shareholder Activism Escalates - The Globe and Mail
EVGN (Nasdaq: EVGN) raises at-the-market ordinary share offering to $3.29M - Stock Titan
Activist investors target Evogene (NASDAQ: EVGN) board as ATM capacity rises - Stock Titan
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):